-
In 1998, Beyth and colleagues developed a modified outpatient bleeding risk index. In this prospective study conducted at the University of Ottawa, 222 patients with diagnosed pulmonary embolism or deep venous thrombosis were observed for an average of 18.5 months.
-
The FDA has approved Genentechs omalizumab, the first biotechnology drug for the treatment of asthma.
-
Metformin and Thiazolidinedione Use in Medicare Patients with Heart Failure; Alcohol Consumption Patterns and Biologic Markers of Glycemic Control Among 459 Women; Azelaic Acid Gel as a New Treatment for Papulopustular Rosacea
-
The ECG in the Figure was obtained from a 57-year-old woman with palpitations. Is there a short run of VT (ventricular tachycardia) in lead V1? What else may be wrong with the tracing?
-
Serum prostate-specific antigen (PSA) testing is frequently used in early detection programs for prostate cancer. While PSA testing has resulted in an increase in prostate cancer detection, its routine use has been questioned because of a lack of specificity. The objective of this study was to determine whether year-to-year fluctuations in prostate-specific antigen levels are due to natural variation and render a single PSA test result unreliable.
-
Jneid and associates critically analyzed the results of the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study and several other antiplatelet trials to provide guidance to the physician regarding the use of aspirin and/or clopidogrel in patients with ACS.
-
Pulmonary function can help predict cardiovascular death risk in individuals in the intermediate-risk group of Framingham Risk Scores.
-
Dabigatran is indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
-
Lifetime surveillance is required after successful treatment of childhood cancers, since up to 75% of survivors develop serious complications and other late effects.
-
Marine n-3 PUFAs act as pleiotropic agents on the cardiovascular system with a diverse range of effects most of which are beneficial for patients with known cardiovascular disease and possibly, they may even have beneficial effects with regard to the primary prevention of cardiovascular disease.
